January 8, 2026
January 8, 2026 —
UC San Diego has received a $7.4 million grant to support the development of a first-of-its-kind stem cell-based gene therapy for Friedreich’s ataxia, a rare inherited neurodegenerative disease that causes progressive loss of coordination, muscle strength, heart function and overall mobility.
December 10, 2025
December 10, 2025 —
A new UC San Diego School of Medicine study offers a unified biological model to explain how genetic predispositions and environmental exposures converge to cause autism spectrum disorder.
November 25, 2025
November 25, 2025 —
University of California San Diego has identified 11 genetic regions linked to delay discounting — the tendency to prefer smaller, immediate rewards over larger, delayed ones — shedding new light on how impulsive decision-making relates to both mental and physical health.
November 11, 2025
November 11, 2025 —
In an analysis of more than 6,800 colon cancer patients across all University of California Health sites, researchers found that those taking glucagon-like peptide-1 (GLP-1) medications were less than half as likely to die within five years compared to those who weren’t on the drugs (15.5% vs. 37.1%
October 30, 2025
October 30, 2025 —
Patients referred to a diabetes management and education clinic led by pharmacists saw meaningful improvements in blood sugar levels over time, underscoring the critical role pharmacists can play in supporting this high-risk group.
October 13, 2025
October 13, 2025 —
A culturally adapted behavioral intervention delivered in Spanish by community health workers significantly reduced unhealthy alcohol use among Latinx adults.
September 30, 2025
September 30, 2025 —
UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences has moved up three spots from last year to No. 4 in national rankings for research funding, according to data reported by the American Association of Colleges of Pharmacy (AACP).
September 24, 2025
September 24, 2025 —
Researchers from UC San Diego School of Medicine found that testing for lipoprotein(a) — a genetic risk factor for heart disease — remains uncommon in the United States, despite modest increases over the past decade.
